期刊文献+

建立数据监查委员会对多中心临床试验的价值

The Importance of Data Monitoring Committees for Multi-Centre Clinical Trials
下载PDF
导出
摘要 随着我国多中心临床试验数量日益增多,为保护受试者的安全与研究数据的完整性,防止多中心临床试验过程发生偏倚,往往需要对临床试验进行独立和持续的监测。因此,有必要建立与之对应的数据监查委员会(Data Monitoring Committee,DMC)来负责这些任务。本文主要通过介绍DMC的组成、独立性、利益冲突、会议形式、审查研究进展、数据质量、安全性与有效性结果、在期中分析中的作用以及对试验数据的评价,探讨在多中心临床试验建立DMC的意义和价值。 With the increasing of multi-center clinical trials in China,independent and continuous monitoring of clinical trials is often required to protect the safety of subjects and the integrity of research data and prevent bias in the process of multi-center clinical trials.Therefore,it is necessary to set up a corresponding Data Monitoring Committee(DMC)to take charge of these tasks.This paper discusses the significance and value of DMC established in multi-center clinical trials by introducing the composition,independence,conflict of interest,meeting format,review of research progress,data quality,safety,effectiveness results,effect in interim analysis,and evaluation of trial data.
作者 韩月浩 冯龙飞 HAN Yue-hao;FENG Long-fei(College of Chemical and Biological Engineering Yichun University,Yichun 336000,China;Institute of Cosmetic Medicine,Yichun University,Yichun 336000,China)
出处 《中国合理用药探索》 CAS 2021年第1期34-37,共4页 Chinese Journal of Rational Drug Use
关键词 数据监查委员会 临床试验 多中心临床试验 期中分析 监察 Data Monitoring Committee clinic trial multi-centre clinical trial interim analysis monitoring
  • 相关文献

参考文献5

二级参考文献28

  • 1王文,马丽媛,邹效漫.国际多中心临床试验的监查[J].中国临床药理学与治疗学,2004,9(7):835-837. 被引量:9
  • 2袁方.我国开展国际多中心临床试验的现状及改进措施[J].医药导报,2007,26(1):100-102. 被引量:22
  • 3HIBBERD P L, WEINER D I.Monitoring participant safety in phase Ⅰ and Ⅱ interventional trials:Options and controversies.J Investig Med,2004,52(7):446-452.
  • 4MCLEMORE M R.The role of the data safety monitoring board:Why was the avastin phase Ⅲ clinical trial stopped. Clin J Onco Nurs,2006,2:153-154.
  • 5Guidamce for Clinicla Trial Sponsors:Establishment and technical guidance of Data and safety monitoring Board. SFDA. 2006.
  • 6WILLIAMS G W,DAVIS R L,GETSON A J,et al.Monitoring of clinical trials and interim analyses from a drug sponsor′s point of view.Stat Med,1993,12(5-6):481-492.
  • 7TIJSSEN J G.Monitoring the safety of participants in randomised clinical trials: Basis and methods.Ned Tijdschr Geneeskd,2008,152(12) : 674-678.
  • 8FREIDLIN B,KORN E L,GEORGE S L.Data monitoring committees and interim monitoring guidelines.Control Clin Trials,1999,20(5) : 395-407.
  • 92001 Guidance for clinical trial sponsors on the establishment and operation of clinical trial data monitoring committees. SFDA. 2001.
  • 10AGENCY E M.Guideline on data monitoring committees. EMA,2005.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部